Skip to content

Advertisement

  • Research article
  • Open Access

Glucose metabolite glyoxal induces senescence in telomerase-immortalized human mesenchymal stem cells

  • 1Email author,
  • 2, 3 and
  • 1
Chemistry Central Journal20126:18

https://doi.org/10.1186/1752-153X-6-18

©  Larsen et al 2012

  • Received: 11 November 2011
  • Accepted: 17 March 2012
  • Published:

Abstract

Background

Various by-products of the cellular metabolism, such as reactive carbonyl species (RCS) are potentially harmful to cells and tissues, and play a role in many physiological and pathological processes. Among various RCS is the highly reactive dicarbonyl glyoxal (GO), which is a natural physiological metabolite produced by the auto-oxidation of glucose, and can form covalent adducts known as advanced glycation endproducts (AGE). We have previously reported that GO accelerates ageing and causes premature senescence in normal human skin fibroblasts.

Results

Using a bone marrow-derived telomerase-immortalised mesenchymal stem cell line hMSC-TERT we have observed that an exposure of cells to 0.75 mM and 1 mM GO induces irreversible cellular senescence within 3 days. Induction of senescence in hMSC-TERT was demonstrated by a variety of markers, including characteristic cell morphology and enlargement, vacuolisation, multinucleation, induction of senescence associated β-galactosidase, cell cycle arrest, and increased levels of a cell cycle inhibitor p16. These changes were accompanied by increased extent of DNA breaks as measured by the comet assay, and increased levels of the AGE product, carboxymethyl-lysine (CML). Furthermore, the in vitro differentiation potential of hMSC-TERT to become functional osteoblasts was highly reduced in GO-treated stem cells, as determined by alkaline phosphatase (ALP) activity and mineralized matrix (MM) formation.

Conclusions

The results of our study imply that an imbalanced glucose metabolism can reduce the functioning ability of stem cells in vivo both during ageing and during stem cell-based therapeutic interventions.

Keywords

  • Telomere Length
  • Comet Assay
  • Cellular Senescence
  • Mineralise Matrix
  • Advanced Glycation Endproducts

Introduction

The progressive accumulation of molecular damage is a universal characteristic of ageing [1–3]. Among the main causative agents of damage, such as reactive oxygen species (ROS), nutritional metabolites and biochemical infidelity, the nutritional metabolites are an important source of molecular damage. For example, an imbalance in the intracellular glucose metabolism leads to increased levels of its oxidative breakdown products dicarbonyls glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG) and glucosone. These byproducts of cellular metabolism belong to the chemical group of α-oxoaldehydes but are more commonly classed as reactive carbonyl species (RCS) [4]. Besides being a natural physiological metabolite in the auto-oxidation of glucose, GO can alternatively be formed by lipid peroxidation, the degradation of glycated proteins and DNA oxidation among other reactions [4–9]. GO is also present in food and beverages, and is an increasingly used industrial chemical [7, 10, 11]. The highly reactive carbonyl groups of GO can react with lysine, arginine and cysteine residues of proteins to form covalent adducts known as advanced glycation end-products (AGE), associated with the browning and fluorescence of proteins [4, 5, 12]. The accumulation of AGE-damaged proteins by the carbonyl stress of RCS has been implicated in several age-related pathologies, such as Alzheimer's disease, atherosclerosis, kidney failure, cataract and diabetes [8, 13–15]. The cellular damage induced by GO and other RCS is not only limited to the proteome but may also harm the genome and the lipome by various means [7, 8, 16–18].

We have previously reported that exposures to 1 mM GO or 400 μM MGO leads to accelerated ageing and the appearance of senescent phenotype within 3 days in normal human skin fibroblasts [19, 20]. Ageing and the senescent phenotype in skin fibroblasts were demonstrated by several well established criteria [3], including morphological phenotype, irreversible growth arrest and G2 cell cycle arrest, increased senescence-associated β-galactosidase (SABG) activity, increased H2O2 level, increased Nε-(carboxymethyl)-lysine (CML) level, and altered activities of superoxide dismutase and catalase antioxidant enzymes. We have now utilized this experimental model of induced cellular senescence in vitro for testing the effects of GO on other cell types, especially the mesenchymal stem cells (MSC), which are multipotent stem cells capable of differentiating into a variety of cell types, such as osteoblasts, adipocytes, chondrocytes, myocytes, neuron-like and endothelial-like cells [21, 22].

Here we report the results of our studies on the effects of GO on growth characteristics, macromolecular damage, induction of senescence and reduced differentiation ability of telomerase-immortalised human bone marrow-derived MSC, designated hMSC-TERT [21]. The aim of these studies was to determine how the imbalanced glucose metabolism observed in vivo during ageing and age-related diseases, such as diabetes-2, may have deleterious effects on the survival and differentiation capacity of MSC. Furthermore, this experimental model of a rapid induction of senescence in immortalized cells provides a reproducible and practical approach for future studies on basic molecular mechanisms of ageing and on testing potential interventions.

Experimental

Chemicals, antibodies and kits

1α,25-Dihydroxyvitamin D3 (Vit-D, calcitrol; Sigma #D1530), β-glycerophosphate (CALBIOCHEM #35675), agarose, Low melting point (LMP; Sigma #A9414), Alizarin Red S (Sigma-Aldrich #A5533), alkaline phosphatase (Sigma #P-5931), L-ascorbic acid (Sigma #A4544), p-nitrophenol phosphate (Sigma-Aldrich #N3002), p-nitrophenol standard solution 10 mM (Sigma #N7660), propidium iodide (PI; Fluka #81845), RNase A, Bovine Pancreas (Roche #10109169001), mouse anti-CML (IgG1; Biologo #CML011), mouse anti-human p16INK4a (IgG1; BD-Pharmingen #51-1325GR), polyclonal rabbit anti-mouse immunoglobins, FITC-conjugated (IgG; DAKO #F0232), protein assay DC (BIO-RAD #500-0112) and senescence cells staining kit (Sigma #CS0030).

Cell culture and GO treatment

The cell line used in this study was created by a stable retroviral transduction of human bone marrow-derived mesenchymal stem cells with the catalytic subunit of telomerase with reverse transcriptase activity [21]. The cell line (designated hMSC-TERT) exhibits all known characteristics of bone marrow-derived MSC in vitro and in vivo, and displays an extended lifespan [22].

hMSC-TERT was incubated at 37°C, 5% CO2, 95% atmospheric air and 95% humidity, and were serially passaged at a split ratio of 1:4. The complete normal DMEM culture media contained 2 mM L-glutamine, 4.5 g/L glucose, 10% (v/v) bovine fetal calf serum (FCS), 100 U/mL penicillin and 100 μL/mL streptomycin. At about 90% confluency the cell cultures were split using the trypsin/EDTA method. All experiments were performed at population doubling (PD) levels between 52 and 145. Unless otherwise stated, the medium was changed every three days, cells were seeded with a density of 5200 cells/cm2 and the cells were always allowed to grow for 24 h after seeding before any treatments with GO was given. The duration of GO treatment was 3 days unless otherwise noted. Cell viability was determined by MTT assay, which showed that doses of up to 1 mM GO were not cytotoxic, but at higher doses, the cells would shrink and die in less than 24 h (data not shown).

Cellular growth analysis

Cells used for the 10-day survival analysis were seeded in several 12-well plates with 8,000 cells per well (~2100 cells/cm2) in normal medium. After 24 h, the culture medium was replaced with either fresh normal medium or the medium containing 0.75 mM GO or 1 mM GO. The treatment was continued either for 10 days or for 3 days followed by the replacement of the GO-containing medium with the normal medium for the remaining 7 days. Three replicates of wells for each condition were trypsinized and counted after 1, 3, 5, 7 and 10 days of treatment. Cell counting was performed in triplicates, using a Bürker-Türk hemocytometer.

Cellular morphology analysis

The cells were seeded in a 6-well plate with 50,000 cells per well (~5200 cells/cm2). After 24 h the cells were treated with various doses of GO for 3 days and then observed for morphological appearance, using a phase-contrast microscope. The cell size distribution was determined by FACS analysis. The senescence-associated β-galactosidase (SABG) assay was performed using the histochemical staining kit from Sigma-Aldrich [23].

Cell cycle analysis by PI staining and flow cytometry

The cells were seeded in a 6-well plate, and after 24 h treated with various doses of GO for 3 days. The cells were trypsinized, resuspended in 1 mL normal medium before centrifugation at 300 × g for 5 min, and the supernatant was carefully removed in order not to disrupt the fragile pellet. The cells were fixed in 70% cold ethanol for 1 h at 4°C, were centrifuged again and were resuspended in 1 mL PBS. In order to degrade any double stranded RNA before the PI staining, 100 μL RNase A (100 μg/mL) was added and the cells incubated for 15 min at 37°C without CO2. Thereafter, 400 μL PI (50 μg/mL) was added and the cells were incubated for 1 h at room temperature (RT) in dark. During the flow cytometry analysis the cells were sorted from debris by FSC and SSC gating and any doublets were sorted out by pulse processing by using the PI-height and PI-area. The data were collected in linear scale and the percentage of cells in different cell cycle phases was defined by Watson pragmatic model fit by Flow Jo (Tree star Inc.)

p16 and CML detection by immunofluorescence and flow cytometry

The cells were seeded in 6-well plates, and after 24 h the cells were treated with various doses of GO for 3 days. The cells were trypsinized and resuspended in 1 mL wash buffer (PBS with 5% FCS) before centrifugation at 600 g for 5 min, fixed first in 150 μL 0.25% PFA for 20 min at 4°C then washed twice and fixed again with 150 μL 70% cold methanol for 1 h at 4°C, washed and then permeabilised with 150 μL 0.25% Triton x-100 for 5 min on ice, washed again before incubating for 30 min at RT with primary antibody. For p16 detection 100 μL of 1:10000 mouse anti-human p16INK4a was used in 10% FCS-PBS to a final concentration of 25 ng/mL. For CML detection, the mouse anti-CML was diluted 1:10000 in 10% FCS-PBS to a final concentration of 25 ng/mL. The cells were washed twice before adding 100 μL solution of the FITC-conjugated secondary anti-mouse antibody and incubated 30 min at RT in dark. The secondary antibody was diluted 1:40 in 10% FCS-PBS, according to manufacturer's recommendations, resulting in the final concentration of 75 μg/mL. The cells were washed and resuspended in 1 mL wash-buffer and were analysed immediately by flow cytometry, as described above. The data are presented as geometric mean values of fluorescence intensity, as collected on a logarithmic scale, and the CV (coefficient of variation (CV) representing the peak width are included.

Comet assay

This variant of the assay was as modified by Singh et al. 1988 [24]. The cells were seeded in a 6-well plate, and after 24 h the cells were treated with various doses of GO for 24 h or 3 days. The positive controls were prepared by adding 0.2 mM H2O2 for 20 min. After treatment, the cells were trypsinized and counted, and 50,000 cells from each sample were resuspended in 1 mL PBS and centrifuged for 1 min at 1000 g. The supernatant was removed and the cells were resuspended in 100 μL low melting point (LMP) agarose, which had been melted and maintained at 37°C in water-bath before use. 75 μL of this LMP agarose cell-suspension was added on top of previously prepared normal melting point (NMP) agarose slides. The thin NMP agarose-coating reduces the chance of the LMP agarose layer to fall off during the procedure. The cell-suspension was added very quickly before the LMP agarose hardened. A coverslip was added on top and the slides were placed at 4°C for 10 min for agarose to harden. The coverslips were gently removed and the slides submerged in lysis solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris base, pH 10) at 4°C for 2 h and kept in dark. The slides were gently rinsed in water and placed in electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH > 13) at 4°C for 40 min to allow unwinding. The electrophoresis was done at 15 V (0.8 V/cm) and 300 mA at 4°C for 20 min. The slides were gently washed three times in neutralization buffer (0.4 M Tris base, pH 7.5) for 5 min and then dehydrated twice in 100% ethanol for 5 min at RT. 20 μL ethidium bromide (10 mg/mL) was added to each sample and coverslips applied. The extent of DNA damage was evaluated under UV light by using a fluorescence microscope, and several pictures were taken to represent at least 50 cells per sample from different areas on the slide. Cells near the slide-edges were avoided due to electrophoresis-distortion in these areas. The pictures were analyzed by image analysis software (AutoComet Cometscore Freeware version 1.5 of Tritek Corporation). The cutoff value was adjusted to avoid saturation but kept constant in all samples. The full length and the head-centre of each comet were designated by a drag-box and the percentage of DNA in each comet tail quantified by the software.

Alkaline phosphatase activity assay

An established marker for osteoblastic differentiation is the expression and activity of alkaline phosphatase (ALP) after treatment with Vit-D or calcitrol [22]. The cells were seeded in T25 flasks with 52,000 cells per flask (~2100 cells/cm2). After 24 h the cells were treated with various doses of GO for 3 days. The cells were trypsinized, counted and reseeded in 12-well plates with precisely 8,000 cells per well (~2100 cells/cm2). Preliminary experiments showed that this reseeding step for cells was necessary to avoid crowding in order for optimum ALP detection. After 24 h the normal medium was replaced with medium containing Vit-D (10-8 M). The cells were cultured for 7 days after which two of the three replicates were used for the ALP assay and one was used for protein quantification.

The ALP activity was measured by washing the cells twice with PBS, adding 250 μL alkaline buffer solution per well, and incubating the cells for 10 min at 37°C to increase the pH. 250 μL of ALP substrate solution (5 mM pNPP diluted in alkaline buffer solution) was added and the plates incubated for 30 min at 37°C. The commercial ALP used for a standard curve had been sub-diluted in the range from 5 × 10-5 U/μL to 6.25 × 10-8 U/μL in 200 μL of the same substrate solution and incubated in a 96-well plate, simultaneously with the samples. Two aliquots of 200 μL from each well were transferred to the 96-well plate and the plate was read in a microplate reader at A415 nm with A595 nm as a reference. To level out the difference in density from the GO induced growth arrest, the average ALP activity from each replicate was related to the corresponding cellular protein concentration in the samples.

Mineralised matrix assay

Mineralised matrix (MM) is formed during osteoblastic differentiation when the osteoblasts mineralise. In this modified assay, MM formation was induced by incubating the cells for 10 days with complete DMEM containing 50 μg/mL L-ascorbic acid, 10 mM β-glycerophosphate, and 10-8 M Vit-D (MM culture conditions) [22]. The presence of calcium was detected by staining with the dye Alizarin Red S which binds selectively to calcium salts. The cells were seeded in 12-well plates with 8,000 cells per well (~2100 cells/cm2). After 24 h the cells were treated with various doses of GO for 3 days then the medium was changed for the MM culturing medium. The Alizarin red S staining was performed by washing the cells three times with PBS, fixing with 70% ethanol for 1 h at -18°C, washing with dH2O and staining with 0.5 mL 40 mM Alizarin Red S, pH 4.2 (dissolved in dH2O) for 1 h at RT on a shaker. The cells were washed thoroughly five times with dH2O to remove unspecific staining and incubated in 10% (wt/vol) cetylpyridinium chloride (CPC) (dissolved in dH2O) for 1 h to elute the stain. The absorbance of the eluted stain was measured in 200 μL aliquots in a microplate reader at A595 nm and related with an Alizarin Red S standard curve of 0-10 mM sub-dilutions in 10% CPC. All samples were within the linear interval of the standard curve. The values from each condition was normalised with the corresponding cellular protein concentration from the sample, and the data were presented as mM Alizarin Red S/μg total protein.

For protein quantification the cells were lysed by a CHAPS-based lysis buffer and the protein was estimated by the DC Protein Assay kit from BIO-RAD according to manufacturer's protocol. All samples were related with a standard curve of BSA subdilutions in the range of 0-2 mg/mL.

Statistical analysis

All statistical analysis in this study were performed by Student's paired t-test, as the compared cell populations are considered to be matched since they have the same origin. Figures marked with single or double asterisks indicate significant different groups from the control indicated in the figure legend, * = p < 0.01, ** = p < 0.05.

Results

Induction of cellular senescence in hMSC-TERT

Exposure of telomerase immortalized hMSC-TERT cells to GO resulted in the induction of senescence within 3 days, as judged by several criteria. The selection of GO doses (0.75 mM and 1 mM) was made on the basis of a MTT assay performed on hMSC-TERT and on our previously published results on human skin fibroblasts [19, 20]. Figure 1 shows that GO-treated cells attained typical in vitro senescent cell morphology in terms of becoming significantly large, irregular, flattened, vacuolated, multinucleated and heterogeneous. Although these morphological changes could also be seen in cells treated with 0.75 mM GO, the effects were more dramatic after treatment with 1 mM GO (Figure 1, upper panel). Furthermore, this GO-induced senescent phenotype was maintained even after the removal of GO during the follow up period of 3 days (Figure 1, lower panel). The increased heterogeneity of the cellular size was obvious in cell suspension (Figure 2, upper panel), and was further confirmed and quantified by flow cytometry (Figure 2, lower panel). There was a clear increase in the proportion of large cells within a cell population with increasing doses of GO, as measured by the shift in the mean value of the forward scatter. Average cell size was also quantified using an automated cell counter (Countess®, Invitrogen). After 3 days of GO treatment the average cell sizes were 21.8 μm, 23.7 μm and 28.7 μm for the control, 0.75 mM and 1 mM GO-treated cells, respectively (data not shown).
Figure 1
Figure 1

Cellular morphology of hMSC-TERT after GO treatment. The upper panel shows cell enlargement, vacuolation and an increased heterogeneity after 3 days of treatment with 0.75 mM and 1 mM GO. The lower panel shows that after 3 days of GO treatment, followed by 3 days in normal medium without GO, the treated cells did not revert back to the normal morphology and maintained a senescent appearance. Pictures were taken using a 10× objective lens on a phase-contrast microscope.

Figure 2
Figure 2

Increase in hMSC-TERT cell size and heterogeneity with GO treatment in suspension (upper panel, 10× objective lens), and confirmed by FACS analysis (lower panel). The increase in the average value of the forward scatter with GO treatment indicates an increase in average size. The coefficient variation (CV) was 16%, 17% and 24%, respectively.

Another cellular biomarker of senescent cells is the increase in the senescence associated β-galactosidase (SABG) activity [23]. The number of SABG-positive cells was counted among at least 500 cells in each sample in two independent experiments. Figure 3 shows that there was a several fold increase in the number of SABG-positive cells after GO-treatment for 3 days (4.5- and 9.2-fold increase for 0.75 mM and 1 mM GO, respectively).
Figure 3
Figure 3

Percentage of senescence associated β-galactosidase (SABG) positive hMSC-TERT after 3 days of GO treatment. Data from two independent experiments are presented as Ex1 and Ex2, respectively.

The effect of GO on growth rate was determined by a 10-day cell growth assay where the cells were treated either continuously or only during the first 3 days with 0.75 mM and 1 mM GO. Figure 4 shows that whereas the number of cells in untreated control cultures increased about a hundred-fold during the 10-day period, a continuous treatment with GO resulted in an almost total inhibition of cell growth and proliferation during this period. However, if the GO treatment was limited to 3 days followed by replacement with normal culture medium, there was some increase in cell number in 0.75 mM treated cultures, but almost no increase in 1 mM-treated cultures, during the following 7 days. It is not clear if the recovery in growth of 0.75 mM-treated cultures after 7 days is due to a sub-set of resistant cells or whether all cells were able to recover from GO-induced cell growth inhibition after removal of GO.
Figure 4
Figure 4

Effect of GO on growth and proliferation of hMSC-TERT during a period of 10 days. Cells were either treated with GO for 3 days followed by 7 days in normal medium or were treated with GO continuously for 10 days. The growth curve for the untreated control is shown broken in order to represent the large change in the scale for cell numbers on Y-axis.

Another parameter and biomarker of cellular senescence in vitro is the cell cycle arrest dynamics including an increased level of cell cycle inhibitor p16 [25]. We have analysed the cell cycle distribution and the levels of p16 of GO-treated and untreated hMSC-TERT by immunofluorescence and FACS analysis. This experiment does not distinguish between the normal dividing cells in the G1 phase of the cell cycle and those which have entered irreversible G0. The distribution of phases by the Watson Pragmatic model was determined by flow cytometry analysis software after PI staining. The cells were gated by their FSC and SSC to represent the main population and to avoid debris. Hereafter they were pulse processed to avoid cell aggregates by gating according to the area (FL2-A) and width (FL2-W) of the pulse signal from the fluorescence detector (not shown). To distinguish between the 2 n and 4 n DNA content in the cells, the characteristics of PI fluorescence (FL2-H) were related with cell number and the percentage of cells in each phase was calculated according to the Watson pragmatic fit model by Flow-Jo software [26].

Figure 5 shows that 1 mM GO treatment caused the growth arrest in hMSC-TERT cells as the frequency of cells in G2/M-phase increased from 1.33% to 13.26%. A slight increase in the frequency of cells in the S-phase was not caused by an increased number of cells entering into this phase (as also observed with the reduced growth rates), but rather it indicates that the S-phase progression is severely delayed [27]. The observed growth arrest in GO-treated cells was further supported by the observation that the levels of the cell cycle check point marker p16 increased by 61% in hMSC-TERT cells treated with 0.75 mM and 1 mM (Figure 6).
Figure 5
Figure 5

Frequency (%) of cells in different phases of the cell cycle in untreated control and in GO-treated hMSC-TERT cells (3 days, 1 mM). The frequency is calculated by the Watson pragmatic fit model by the Flow-Jo software according to the 2 n and 4 n peaks from a histogram relating the PI fluorescence with cell number.

Figure 6
Figure 6

Changes in the levels of p16 in hMSC-TERT after 3 days of GO treatment. The upper panel shows FACS-distribution of fluorescence intensity, whose geometric mean values are presented in the histogram in the lower panel. The coefficient variation (CV) was 71%, 54% and 55%, respectively.

Induction of macromolecular damage in hMSC-TERT by GO

The extent of DNA damage induced by GO was determined by the comet assay, which measures the prevalence of single- and double-strand breaks. The level of DNA damage was estimated from the percentage of DNA in the tails of the comets formed after the single-cell gel electrophoresis as broken DNA moves faster in the current (Figure 7). The percentage of DNA in the tails versus the core was analyzed by Tritek Cometscore Freeware version 1.5., and the results show that hMSC-TERT cells treated with GO for 3 days had significantly higher levels of damaged DNA than the untreated cells (Figure 8). As the positive control, DNA damage was induced in the cells by treatment with 0.2 mM H2O2 for 20 min. All samples were significantly different from the untreated controls as calculated by Student's paired t-test.
Figure 7
Figure 7

Induction of single- and double-stranded DNA damage in hMSC-TERT treated with GO for 24 h, as determined by the comet assay. The positive control was with 0.2 mM H2O2 (HP) treatment for 20 min. Pictures were taken with a 10× objective lens.

Figure 8
Figure 8

Extent of DNA damage measured as the percentage of tail DNA in the comet assay in hMSC-TERT cells treated with GO for 3 days. Cells exposed to 0.2 mM H2O2 (HP) for 20 min, or to 0.75 mM and 1 mM GO for 3 days were significantly different from the untreated controls, as calculated by paired t-test (n = 96, * = p < 0.01). The error bars indicate standard deviation.

Nε-Carboxymethyl-Lysine (CML) adducts are the most prevalent form of AGEs, and previous studies have shown that CML adduct formation is induced by GO [28]. The levels of CML adducts was determined in two independent experiments, using immunofluorescence and flow cytometry. Figure 9 (upper panel) shows the fluorescence intensity distribution from one experiment, and the histogram (lower panel) shows the geometric mean values of the fluorescence intensity in GO-treated and control cells from the same experiment. There was about a 2-fold increase in CML adducts in GO-treated hMSC-TERT in both experiments.
Figure 9
Figure 9

FACS-based measurement of the levels of CML adducts in hMSC-TERT cells after 3 days of GO treatment. The geometric mean values are presented in the histogram in the lower panel. The coefficient variation (CV) was 53%, 42% and 45%, respectively.

Impaired osteoblastic differentiation of hMSC-TERT by GO

To determine the effects of GO on the osteoblastic differential potential, two markers of differentiation, ALP and MM, were analysed in hMSC-TERT cells after exposure to appropriate conditions for the induction of differentiation. The quantified activity of ALP was related to a pNP standard curve and then related to the cellular protein content of the sample in order to take the reduced growth of the GO samples into consideration. The results were normalised against the value of the undifferentiated control for comparison. The assay was performed five times representing a broad range of population doubling levels (PDL 72, 93, 95 104 and 135), each performed with two replicates. All experiments showed the same tendency of significantly reduced differentiation in the GO-treated samples, despite an apparently large variation. Figure 10 shows that a pretreatment of hMSC-TERT cells with GO for 3 days reduced the extent of osteoblastic differentiation, on an average, by 61% in 0.75 mM GO-treated cells and by 97% in 1 mM GO-treated cells, as compared with the extent of differentiation in untreated controls.
Figure 10
Figure 10

Effect of GO on ALP activity (relative arbitrary units) as a marker of osteoblastic differentiation of hMSC-TERT cells. ALP levels in 0.75 mM and 1 mM GO-treated cells were significantly different from the differentiated control as calculated by paired t-test (n = 10, * = p < 0.01). The error bars indicate standard deviation. (D: differentiated; U: undifferentiated)

The extent of formation of MM as a marker of osteoblastic differentiation was determined by Alizarin Red S-calcium complex formation, which was quantified by absorbance after eluting the stain with cetylpyridinium chloride (CPC). The quantified Alizarin red S staining in each sample was related to a standard curve, and then to the total cellular protein content of the sample. Figure 11 shows the microscopic pictures of hMSC-TERT induced to produce MM under various conditions. A pretreatment of cells to GO almost completely inhibited the formation of MM (Figure 12).
Figure 11
Figure 11

Effect of GO on mineralized matrix (MM) formation as a marker of osteoblastic differentiation, as detected by staining with Alizarin red S. The upper panel of 8 wells is a whole-plate photograph with two replicates of each condition. The lower panel shows pictures of MM formation in undifferentiated and differentiated control cells, and in cells pretreated with GO for 3 days (10× objective lens)

Figure 12
Figure 12

Effect of GO on the extent of mineralized matrix (MM) as a marker of osteoblastic differentiation. The experiment was performed 4 times, each time with two replicates. In each experiment, all values were normalised to the corresponding cellular protein content. hMSC-TERT cells pretreated with GO (0.75 mM and 1 mM for 3 days) were significantly different from the differentiated control, as calculated by paired t-test (n = 8, ** = p < 0.05). The error bars indicate standard deviation. (D: differentiated; U: undifferentiated)

Discussion

In the present study, we have extended the previous observations made on the normal human skin fibroblasts [19] to immortalized MSC showing that the glucose metabolite GO causes molecular damage to DNA and proteins, and leads to the rapid emergence of a senescent phenotype in cells in vitro. Using a bone marrow-derived telomerase-immortalised mesenchymal stem cell line hMSC-TERT we have now shown that an exposure of cells to 0.75 mM and 1 mM GO induces irreversible cellular senescence within 3 days. Induction of cellular senescence in hMSC-TERT was demonstrated by a variety of well established markers, such as characteristic senescent morphology and enlargement, increased vacuolisation, multinucleation, SABG activity, cell cycle arrest, and increased levels of a cell cycle inhibitor p16 [3]. The increase in the extent of single- and double-strand DNA breaks as measured by the comet assay, and increased levels of the AGE product CML in cells appear to contribute as causative agents to the GO-induced senescence among other potential mechanisms. Other studies performed on keratinocytes support our observations that GO treatment increases the level of DNA breaks [17]. Our observations of increased DNA damage and CML formation are in line with the well-established fact that increased levels of macromolecular damage, whether spontaneously accumulated during serial passaging or induced by high levels of stress, results in the upregulation of several cell cycle check point regulators [25, 29, 30]. Especially the elevated levels of p16 and p21 are characteristic markers of cellular senescence in vitro and in vivo. Additionally, p16 in particular may play a role in the initiation of the senescence programme [31, 32].

Functional assays with respect to the differentiation potential of hMSC-TERT cells to osteoblastic phenotype in vitro showed that GO-treated stem cells had highly reduced ability to become functional osteoblasts, as determined by ALP activity and MM formation. It is well known that during ageing bone remodeling is significantly imbalanced, and often leads to the onset of osteoporosis [33]. The reasons considered for reduced bone formation during ageing include a reduced MSC niche, an increase in bone-marrow adiposity, osteoblastic apoptosis, and increased number of active osteoclasts [34]. As regard to the role of hMSC, studies indicate that it is primarily the decreased proliferative capacity of hMSC and the changes in the bone micro-environment which are responsible for the age-related changes in osteoblast function [35, 36]. Additionally, age-related pathologies, such as imbalanced glucose metabolism leading to diabetes-2, further enhance the problems of altered bone remodeling. The results of our present study imply that an imbalanced glucose metabolism can reduce the functioning ability of stem cells in vivo both during ageing and during stem cell-based regenerative therapy.

Our study was performed with a telomerase-immortalized stem cell-line which possesses an unlimited replicative potential due to its constitutively active telomerase [21]. However, it is well known that one of the reasons for the replicative senescence of normal cells is a progressive loss of telomeres during repeated cell proliferation, associated with a lack of telomerase activity [37, 38]. For example, in the case of normal cultured hMSC from a 33 yr old donor, an average of 88 telomeric base pairs was lost per PD during serial expansion, leading to increased genomic instability and final growth arrest after 26 PD [39]. Furthermore, telomeres also have increased sensitivity to oxidative damage due to lack of adequate repair mechanisms in the telomere region [40]. Studies performed on other cell types have shown increased rates of telomere shortening caused by single-strand breaks when cells were treated with oxidative stressors such as H2O2 [41] or hyperoxia [42].

Since we had observed that GO increased the levels of DNA damage in hMSC-TERT, we made some preliminary investigations on the potential damaging effect of GO on telomere length and telomerase activity, by using a TRF assay and a RQ-TRAP assay [43], respectively. Although there was some decrease in telomerase activity, there was no detectable difference in telomere length after three days of GO treatment (data not shown). This inconsistency between reduced telomerase activity and unaltered telomere length can be explained by the fact that telomerase is constitutively and ectopically expressed in the hMSC-TERT cell line, and thus the residual activity may be sufficient to uphold the telomere length. Another reason for this can be the reduced proliferation of GO-treated cells. With fewer cycles of DNA replication less of the telomere length will be lost, despite a reduced activity of telomerase. The fact that the telomeres did not show shortening after GO treatment indicates that it did not cause significant damage to the telomeres, and so the observed GO-induced senescence can be characterized as being telomere-independent.

Based on our observations that GO can induce senescence in normal and immortalized cells, it is interesting to consider the human exposure to reactive carbonyl species (RCS) in general. The primary sources of exposure to RCS are the endogenous production or dietary uptake. The main concern of RCS is its ability to glycate both cellular and extracellular proteins, resulting in the formation of advanced glycation end-products (AGEs). Both AGE and RCS are considered to play a crucial role in several age-related pathological conditions including diabetes, Alzheimer's disease and cardiovascular diseases [13–15]. With respect to diabetes, the hyperglycemic state causes increased auto-oxidation of glucose to form elevated levels of RCS glyoxal and methylglyoxal in the blood plasma of diabetes patients [44, 45], which may contribute to the long-term complications of this disease, including cataracts and atherosclerosis. The RCSs are highly capable of modifying lysine, cysteine and especially arginine residues as they do so with high reaction rates [46]. Because arginine is present in high abundance in the functional sites of many proteins, GO may disrupt their functionality by reducing enzymatic activity, receptor-ligand or protein-nucleotide binding. It may, however, be the extracellular proteins which are most susceptible to glycoxidative stress, due to their low turnover rate. Furthermore, studies performed on diabetic rats have shown a 5-fold increase in GO-derived modification of a specific arginine in the extracellular protein collagen IV [4]. This arginine is important for the assembly and stability of the collagen IV network, which influences the thickness of the basement membrane in capillaries and small vessels. Other studies have shown that AGE-forming inhibitors reduce the formation of atherosclerotic plaques in the aortas of diabetic mice [47]. The RCS-induced formation of AGEs could thus be influencing the vascular complications observed in diabetes patients.

Besides the endogenous metabolic exposure to GO due to glucose auto-oxidation, the dietary exposure of RCS may be hazardous to human health. RCSs may be formed in large quantities during the thermal processing of foods, such as roasting, frying and baking. The levels of both GO and MGO have been found to increase with increased baking time and heat exposure in cookies [10]. Another source of high dicarbonyl exposure is the carbonated soft drinks containing high fructose corn syrup [11]. It is important to investigate if the exposure to these RCS contaminants in our diet could influence our susceptibility to age-related human diseases by inducing premature senescence in both differentiated cells and stem cells.

Finally, the results of our current study demonstrate that the glucose metabolite GO can induce cellular senescence in stem cells similar to the stress-induced premature senescence (SIPS) model [48]. Our in vitro model of GO-induced senescence in telomerase-immortalized human mesenchymal stem cells may be similarly utilized in ageing interventional studies. The combination of an immortal cell line with the ability to rapidly induce ageing at any chosen time-point, can open up several practical possibilities for testing potential ageing modulatory natural and synthetic compounds.

Declarations

Acknowledgements

We thank Cristovao Lima, Alex Schmitz, Basem Abdallah, Hamid Saeed, Maria Harbo and Anders Olsen for their help and advice.

Authors’ Affiliations

(1)
Laboratory of Cellular Ageing, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
(2)
Laboratory for Endocrinology, Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
(3)
Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia

References

  1. Rattan SI: Increased molecular damage and heterogeneity as the basis of aging. Biol Chem. 2008, 389: 267-272.View ArticleGoogle Scholar
  2. Rattan SI: Biogerontology: from here to where? The Lord Cohen Medal Lecture-2011. Biogerontology. 2012, doi:10.1007/s10522-011-9354-3Google Scholar
  3. Rattan SI: Cellular senescence in vitro. Encyclopedia of Life Sciences. 2012, doi:10.1002/9780470015902.a0002567.pub3Google Scholar
  4. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, Madu H, Stec D, Hudson B, Voziyan P: Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. Biochemistry. 2011, 50: 6102-6112. 10.1021/bi200757d.View ArticleGoogle Scholar
  5. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry. 1995, 34: 3702-3709. 10.1021/bi00011a027.View ArticleGoogle Scholar
  6. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J. 1999, 344 (Pt 1): 109-116.View ArticleGoogle Scholar
  7. Olsen R, Molander P, Ovrebo S, Ellingsen DG, Thorud S, Thomassen Y, Lundanes E, Greibrokk T, Backman J, Sjoholm R, Kronberg L: Reaction of glyoxal with 2'-deoxyguanosine, 2'-deoxyadenosine, 2'-deoxycytidine, cytidine, thymidine, and calf thymus DNA: identification of DNA adducts. Chem Res Toxicol. 2005, 18: 730-739. 10.1021/tx0496688.View ArticleGoogle Scholar
  8. Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M: Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev. 2007, 27: 817-868. 10.1002/med.20073.View ArticleGoogle Scholar
  9. Turk Z: Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiologi Res/Academia Scientiarum Bohemoslovaca. 2010, 59: 147-156.Google Scholar
  10. Arribas-Lorenzo G, Morales FJ: Analysis, distribution, and dietary exposure of glyoxal and methylglyoxal in cookies and their relationship with other heat-induced contaminants. J Agric Food Chem. 2010, 58: 2966-2972. 10.1021/jf902815p.View ArticleGoogle Scholar
  11. Tan D, Wang Y, Lo CY, Sang S, Ho CT: Methylglyoxal: its presence in beverages and potential scavengers. Ann N Y Acad Sci. 2008, 1126: 72-75. 10.1196/annals.1433.027.View ArticleGoogle Scholar
  12. Wolff SP, Dean RT: Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. The Biochem J. 1987, 245: 243-250.View ArticleGoogle Scholar
  13. Grillo MA, Colombatto S: Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008, 35: 29-36. 10.1007/s00726-007-0606-0.View ArticleGoogle Scholar
  14. Miyata T, van Ypersele-de-Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999, 55: 399-399.View ArticleGoogle Scholar
  15. Wautier JL, Schmidt AM: Protein glycation: a firm link to endothelial cell dysfunction. Circ Res. 2004, 95: 233-238. 10.1161/01.RES.0000137876.28454.64.View ArticleGoogle Scholar
  16. Kasai H, Iwamoto-Tanaka N, Fukada S: DNA modifications by the mutagen glyoxal: adduction to G and C, deamination of C and GC and GA cross-linking. Carcinogenesis. 1998, 19: 1459-1465. 10.1093/carcin/19.8.1459.View ArticleGoogle Scholar
  17. Roberts MJ, Wondrak GT, Laurean DC, Jacobson MK, Jacobson EL: DNA damage by carbonyl stress in human skin cells. Mutat Res. 2003, 522: 45-56. 10.1016/S0027-5107(02)00232-4.View ArticleGoogle Scholar
  18. Thornalley PJ: Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interac. 2008, 23: 125-150.View ArticleGoogle Scholar
  19. Sejersen H, Rattan SI: Dicarbonyl-induced accelerated aging in vitro in human skin fibroblasts. Biogerontology. 2009, 10: 203-211. 10.1007/s10522-008-9172-4.View ArticleGoogle Scholar
  20. Sejersen H, Rattan SI: Glyoxal-induced premature senescence in human fibroblasts. Ann N Y Acad Sci. 2007, 1100: 518-523. 10.1196/annals.1395.057.View ArticleGoogle Scholar
  21. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M: Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 2002, 20: 592-596. 10.1038/nbt0602-592.View ArticleGoogle Scholar
  22. Abdallah BM, Haack-Sorensen M, Burns JS, Elsnab B, Jakob F, Hokland P, Kassem M: Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite extensive proliferation. Biochem Biophys Res Commun. 2005, 326: 527-538. 10.1016/j.bbrc.2004.11.059.View ArticleGoogle Scholar
  23. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995, 92: 9363-9367. 10.1073/pnas.92.20.9363.View ArticleGoogle Scholar
  24. Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988, 175: 184-191. 10.1016/0014-4827(88)90265-0.View ArticleGoogle Scholar
  25. Johnson DG, Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999, 39: 295-312. 10.1146/annurev.pharmtox.39.1.295.View ArticleGoogle Scholar
  26. Watson JV, Chambers SH, Smith PJ: A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry. 1987, 8: 1-8.View ArticleGoogle Scholar
  27. Bartek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 2004, 5: 792-804. 10.1038/nrm1493.View ArticleGoogle Scholar
  28. Glomb MA, Monnier VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem. 1995, 270: 10017-10026. 10.1074/jbc.270.17.10017.View ArticleGoogle Scholar
  29. Kaul SC, Deocaris CC, Wadhwa R: Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol. 2007, 42: 263-274. 10.1016/j.exger.2006.10.020.View ArticleGoogle Scholar
  30. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE: Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004, 114: 1299-1307.View ArticleGoogle Scholar
  31. Haferkamp S, Becker TM, Scurr LL, Kefford RF, Rizos H: p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging cell. 2008, 7: 733-745. 10.1111/j.1474-9726.2008.00422.x.View ArticleGoogle Scholar
  32. Baker DJ, Wijshake T, Tchkonia T, Lebrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM: Clearance of p16(Ink4a)-positive senescent cells delays ageing-associated disorders. Nature. 2011, doi:10.1038/nature10600Google Scholar
  33. Marie PJ, Kassem M: Extrinsic mechanisms involved in age-related defective bone formation. J Clin Endocrinol Metab. 2011, 96: 600-609. 10.1210/jc.2010-2113.View ArticleGoogle Scholar
  34. Chan GK, Duque G: Age-related bone loss: old bone, new facts. Gerontology. 2002, 48: 62-71. 10.1159/000048929.View ArticleGoogle Scholar
  35. Stenderup K, Justesen J, Clausen C, Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003, 33: 919-926. 10.1016/j.bone.2003.07.005.View ArticleGoogle Scholar
  36. Stenderup K, Rosada C, Justesen J, Al-Soubky T, Dagnaes-Hansen F, Kassem M: Aged human bone marrow stromal cells maintaining bone forming capacity in vivo evaluated using an improved method of visualization. Biogerontology. 2004, 5: 107-118.View ArticleGoogle Scholar
  37. Harley CB: Telomere loss: mitotic clock or genetic time bomb?. Mutat Res. 1991, 256: 271-282.View ArticleGoogle Scholar
  38. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science. 1998, 279: 349-352. 10.1126/science.279.5349.349.View ArticleGoogle Scholar
  39. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I: Study of Telomere Length Reveals Rapid Aging of Human Marrow Stromal Cells following In Vitro Expansion. Stem Cells. 2004, 22: 675-682. 10.1634/stemcells.22-5-675.View ArticleGoogle Scholar
  40. Petersen S, Saretzki G, Zglinicki TV: Preferential Accumulation of Single-Stranded Regions in Telomeres of Human Fibroblasts. Exp Cell Res. 1998, 239: 152-160. 10.1006/excr.1997.3893.View ArticleGoogle Scholar
  41. von Zglinicki T, Pilger R, Sitte N: Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. 2000, 28: 64-74. 10.1016/S0891-5849(99)00207-5.View ArticleGoogle Scholar
  42. Honda S, Hjelmeland LM, Handa JT: Oxidative stress-induced single-strand breaks in chromosomal telomeres of human retinal pigment epithelial cells in vitro. Investig Ophthalmol Vis Sci. 2001, 42: 2139-2144.Google Scholar
  43. Wege H, Chui MS, Le HT, Tran JM, Zern MA: SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 2003, 31: E3-View ArticleGoogle Scholar
  44. Mirza MA, Kandhro AJ, Memon SQ, Khuhawar MY, Arain R: Determination of glyoxal and methylglyoxal in the serum of diabetic patients by MEKC using stilbenediamine as derivatizing reagent. Electrophoresis. 2007, 28: 3940-3947. 10.1002/elps.200700129.View ArticleGoogle Scholar
  45. Lapolla A, Flamini R, Dalla-Vedova A, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P: Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clinical Chemistry and Laboratory Medicine: CCLM/FESCC. 2003, 41: 1166-1173.View ArticleGoogle Scholar
  46. Rabbani N, Thornalley PJ: The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci. 2008, 1126: 124-127. 10.1196/annals.1433.043.View ArticleGoogle Scholar
  47. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, et al: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004, 53: 1813-1823. 10.2337/diabetes.53.7.1813.View ArticleGoogle Scholar
  48. Toussaint O, Medrano EE, von Zglinicki T: Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol. 2000, 35: 927-945. 10.1016/S0531-5565(00)00180-7.View ArticleGoogle Scholar

Copyright

© Larsen et al 2012

Advertisement

BMC Chemistry

ISSN: 2661-801X

Contact us